Developing a new medication to prevent opioid relapse and overdose
Development of the novel mu-opioid receptor antagonist methocinnamox (MCAM) for preventing relapse and overdose
This study is testing a new pill called methocinnamox (MCAM) that helps people recovering from opioid addiction by blocking the effects of opioids, making it easier for them to stay on track and avoid relapse.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Hlth Science Center NIH-funded |
| Lab location | 1 site (San Antonio, United States) |
| Project ID | NIH-11162314 on NIH RePORTER |
What this research studies
This research focuses on the development of methocinnamox (MCAM), a novel medication designed to prevent relapse in individuals recovering from opioid addiction. MCAM works by blocking the effects of opioid drugs, including potent substances like fentanyl, and is intended to be taken orally, making it easier for patients to use. The research includes extensive safety testing in animals and aims to establish MCAM as a long-acting treatment that remains effective for over two weeks with a single dose. The study is also working on ensuring that the medication is stable and effective for patients in need.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults aged 21 and older who are recovering from opioid addiction and are at risk of relapse.
Not a fit: Patients who are not recovering from opioid addiction or who are not opioid users may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new, effective treatment option for individuals recovering from opioid addiction, significantly reducing the risk of relapse and overdose.
How similar studies have performed: Previous research has shown promise in developing opioid receptor antagonists, but the specific approach with MCAM is novel and has not been widely tested.
Where this research is happening
San Antonio, United States
- University of Texas Hlth Science Center — San Antonio, United States (Active)
Researchers
- Principal investigator: France, Charles P — University of Texas Hlth Science Center
- Study coordinator: France, Charles P
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.